A Phase II Trial of Cabozantinib and Erlotinib for Patients With EGFR and c-Met Co-expressing Metastatic Pancreatic Adenocarcinoma
Phase of Trial: Phase II
Latest Information Update: 05 Jun 2018
At a glance
- Drugs Cabozantinib (Primary) ; Erlotinib (Primary)
- Indications Adenocarcinoma; Pancreatic cancer
- Focus Therapeutic Use
- 05 Jun 2018 Trial design presented at the 54th Annual Meeting of the American Society of Clinical Oncology
- 26 Apr 2018 According to an Exelixis media release, data from this trial will be presented at the American Society of Clinical Oncology (ASCO) 2018 Annual Meeting.
- 24 Oct 2017 Status changed from not yet recruiting to recruiting.